Clinical trials of small cohorts have shown that the administration of G-CSF to patients with severe alcoholic hepatitis is safe, reduces disease severity and 90-day mortality and promotes the proliferation of hepatocytes, suggesting the safety and therapeutic efficacy of G-CSF in these patients [174–176]. Here, CSF3 is linked to alcoholic hepatitis.